N/A
Completed N=17
Cytokines in Papillon-Lefèvre Syndrome
Papillon-Lefevre Disease
Source: ClinicalTrials.gov NCT01116934 ↗
Enrolled (actual)
17
Serious AEs
0.0%
Results posted
Mar 2016
Primary outcomePrimary: Serum Concentrations of Interleukin (IL)-1 Beta — 1100.00; 896.21; 65559; 45734 pg/ml
Summary
Papillon-Lefèvre syndrome (PLS) is characterised by aggressively progressive periodontitis combined with palmo-plantar hyperkeratosis. It is caused by "loss of function" mutations in the cathepsin C gene. The hypothesis behind this study is that PLS patients' PMNs produce more proinflammatory cytokines to compensate for their reduced capacity to neutralize leukotoxin and to eliminate Aggregatibacter actinomycetemcomitans. Production of more interleukin (IL)-8 would result in the attraction of more PMNs. Thus, the aim of this study was to evaluate the cytokine profile in PLS patients' blood cultures.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Serum Concentrations of Interleukin (IL)-1 Beta |
1100.00; 896.21; 65559; 45734; 12902.5; 11563 | — |
Eligibility Criteria
Inclusion Criteria
- Diagnose of PLS
Exclusion Criteria
- No written informed consent
Data sourced from ClinicalTrials.gov (NCT01116934). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.